How Do DLBCL Experts Hone Bispecific Antibodies, CAR T-Cell Therapy?

5 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
The subject of the panel discussion on diffuse large B-cell lymphoma (DLBCL) care with Tara Graff, DO, MS, of Mission Cancer and Blood, Ruemu Birhiray, MD, of Hematology Oncology of Indiana, Suzanne Fanning, DO, from Prisma Health Cancer Institute, and Joshua Brody, MD, of the Tisch Cancer Institute at Mount Sinai moves to use of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy. The 4 experts extensively describe how they balance these approaches and determine which is appropriate for a patient, amid considerations such as prior debulking, patient response, and clinical trials.
------------
Blood Cancers Today is a new publication that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. As the online home of the publication, bloodcancerstoday.com is updated daily, with the most current information from around the specialty and multimedia content, including exclusive interviews with presenters at major medical meetings.

Blood Cancers Today was developed to reach all professionals in the hematology/oncology universe, covering the latest news and analysis in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, and other hematologic malignancies.
Category
Oncology
Be the first to comment

Up Next